Research Training in Hematology at UNC Chapel Hill

Abstract: The Hematology T32 Training Grant at the University of North Carolina at Chapel Hill (UNC-CH) remains committed to training both MD physician-scientists and postdoctoral PhD scientists for careers in academic hematology and hematology research. With 5 positions, the program will continue to train the most promising clinical fellows, primarily from adult and pediatric hematology, as well as PhD post-doctoral candidates in areas of traditional institutional research strength that encompass benign hematology. These areas of focus are 1. hemostasis/thrombosis/platelet biology; 2. sickle cell disease/hemoglobinopathies; and 3. transfusion medicine. Both basic bench and clinical research tracks are offered, with carefully selected didactic coursework to complement the training experience. All trainees will complete instruction in scientific rigor and reproducibility, basic biostatistics, and grants writing and scientific presentation. Additional didactic instruction will be individualized for trainees, with bench researchers receiving formalized training in techniques and concepts that are most relevant to their research focus. Trainees with a primary emphasis in clinical research will be expected to carry a heavier course load unless they have previously obtained a Masters in Clinical Research or equivalent qualification. Those without this background will be encouraged to pursue an MSCR degree in the Gillings School of Public Health. The research mission of the recently created ‘UNC Blood Research Center’ encompasses precisely the same areas of focus in non-malignant hematology under a new organizational structure that enhances the opportunities for training and team science. In this competitive renewal, scientific and educational interactions between MD and PhD trainees in the form of conferences, journal clubs, and symposia have been emphasized. Following 2 years of training on the T32 grant, trainees will be encouraged to apply for individual or institutional K series awards, and/or other sources of independent research funding.